ID   PTN7_HUMAN              Reviewed;         360 AA.
AC   P35236; B3KXE1; Q53XK4; Q5SXQ0; Q5SXQ1; Q9BV05;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 3.
DT   12-APR-2017, entry version 168.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 7;
DE            EC=3.1.3.48;
DE   AltName: Full=Hematopoietic protein-tyrosine phosphatase;
DE            Short=HEPTP;
DE   AltName: Full=Protein-tyrosine phosphatase LC-PTP;
GN   Name=PTPN7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   FUNCTION.
RX   PubMed=1510684; DOI=10.1016/S0006-291X(05)81592-X;
RA   Adachi M., Sekiya M., Isobe M., Kumura Y., Ogita Z.I., Hinoda Y.,
RA   Imai K., Yachi A.;
RT   "Molecular cloning and chromosomal mapping of a human protein-tyrosine
RT   phosphatase LC-PTP.";
RL   Biochem. Biophys. Res. Commun. 186:1607-1615(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Lymphocyte;
RX   PubMed=1530918; DOI=10.1002/eji.1830220134;
RA   Zanke B., Suzuki H., Kishihara K., Mizzen L., Minden M., Pawson A.,
RA   Mak T.W.;
RT   "Cloning and expression of an inducible lymphoid-specific, protein
RT   tyrosine phosphatase (HePTPase).";
RL   Eur. J. Immunol. 22:235-239(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, INTERACTION WITH MAPK1, ACTIVE SITE, AND MUTAGENESIS OF
RP   CYS-291.
RX   PubMed=9624114; DOI=10.1074/jbc.273.25.15340;
RA   Saxena M., Williams S., Gilman J., Mustelin T.;
RT   "Negative regulation of T cell antigen receptor signal transduction by
RT   hematopoietic tyrosine phosphatase (HePTP).";
RL   J. Biol. Chem. 273:15340-15344(1998).
RN   [8]
RP   FUNCTION, INTERACTION WITH MAPK1 AND MAPK3, PHOSPHORYLATION AT THR-66
RP   AND SER-93, AND MUTAGENESIS OF THR-66 AND SER-93.
RX   PubMed=10206983; DOI=10.1074/jbc.274.17.11693;
RA   Saxena M., Williams S., Brockdorff J., Gilman J., Mustelin T.;
RT   "Inhibition of T cell signaling by mitogen-activated protein kinase-
RT   targeted hematopoietic tyrosine phosphatase (HePTP).";
RL   J. Biol. Chem. 274:11693-11700(1999).
RN   [9]
RP   FUNCTION, INTERACTION WITH MAPK1, AND PHOSPHORYLATION AT SER-44.
RX   PubMed=10559944; DOI=10.1038/13024;
RA   Saxena M., Williams S., Tasken K., Mustelin T.;
RT   "Crosstalk between cAMP-dependent kinase and MAP kinase through a
RT   protein tyrosine phosphatase.";
RL   Nat. Cell Biol. 1:305-311(1999).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH MAPK1 AND MAPK3.
RX   PubMed=10702794; DOI=10.1038/sj.onc.1203408;
RA   Pettiford S.M., Herbst R.;
RT   "The MAP-kinase ERK2 is a specific substrate of the protein tyrosine
RT   phosphatase HePTP.";
RL   Oncogene 19:858-869(2000).
RN   [11]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-44, AND MUTAGENESIS OF
RP   SER-44.
RX   PubMed=14613483; DOI=10.1042/BJ20031244;
RA   Nika K., Hyunh H., Williams S., Paul S., Bottini N., Tasken K.,
RA   Lombroso P.J., Mustelin T.;
RT   "Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation
RT   by cAMP-dependent protein kinase in T-cells: dynamics and subcellular
RT   location.";
RL   Biochem. J. 378:335-342(2004).
RN   [12]
RP   MUTAGENESIS OF TYR-125; ASP-257 AND GLN-335.
RX   PubMed=15466470; DOI=10.1074/jbc.M407820200;
RA   Huang Z., Zhou B., Zhang Z.-Y.;
RT   "Molecular determinants of substrate recognition in hematopoietic
RT   protein-tyrosine phosphatase.";
RL   J. Biol. Chem. 279:52150-52159(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-66, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44 AND SER-143, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44; THR-66; SER-110 AND
RP   SER-143, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 65-360 OF MUTANT ASP-246 IN
RP   COMPLEX WITH SUBSTRATE ANALOG.
RX   PubMed=16226275; DOI=10.1016/j.jmb.2005.09.049;
RA   Mustelin T., Tautz L., Page R.;
RT   "Structure of the hematopoietic tyrosine phosphatase (HePTP) catalytic
RT   domain: structure of a KIM phosphatase with phosphate bound at the
RT   active site.";
RL   J. Mol. Biol. 354:150-163(2005).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 65-358 IN COMPLEX WITH
RP   SUBSTRATE ANALOG, AND SUBUNIT.
RX   PubMed=16441242; DOI=10.1042/BJ20051931;
RA   Eswaran J., von Kries J.P., Marsden B., Longman E., Debreczeni J.E.,
RA   Ugochukwu E., Turnbull A., Lee W.H., Knapp S., Barr A.J.;
RT   "Crystal structures and inhibitor identification for PTPN5, PTPRR and
RT   PTPN7: a family of human MAPK-specific protein tyrosine
RT   phosphatases.";
RL   Biochem. J. 395:483-491(2006).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 37-52 IN COMPLEX WITH MAPK1.
RX   PubMed=16765894; DOI=10.1016/j.str.2006.04.006;
RA   Zhou T., Sun L., Humphreys J., Goldsmith E.J.;
RT   "Docking interactions induce exposure of activation loop in the MAP
RT   kinase ERK2.";
RL   Structure 14:1011-1019(2006).
CC   -!- FUNCTION: Protein phosphatase that acts preferentially on
CC       tyrosine-phosphorylated MAPK1. Plays a role in the regulation of T
CC       and B-lymphocyte development and signal transduction.
CC       {ECO:0000269|PubMed:10206983, ECO:0000269|PubMed:10559944,
CC       ECO:0000269|PubMed:10702794, ECO:0000269|PubMed:1510684,
CC       ECO:0000269|PubMed:1530918, ECO:0000269|PubMed:9624114}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- ENZYME REGULATION: Inhibited in cells after FCER1A triggering.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. Interacts with MAPK1, MAPK3 and several other
CC       MAP kinases. {ECO:0000269|PubMed:10206983,
CC       ECO:0000269|PubMed:10559944, ECO:0000269|PubMed:10702794,
CC       ECO:0000269|PubMed:16226275, ECO:0000269|PubMed:16441242,
CC       ECO:0000269|PubMed:16765894, ECO:0000269|PubMed:9624114}.
CC   -!- INTERACTION:
CC       Q2TAC2:CCDC57; NbExp=3; IntAct=EBI-2265723, EBI-2808286;
CC       Q53SE7:FLJ13057; NbExp=3; IntAct=EBI-2265723, EBI-10172181;
CC       P28482:MAPK1; NbExp=6; IntAct=EBI-2265723, EBI-959949;
CC       P47811:Mapk14 (xeno); NbExp=2; IntAct=EBI-2265723, EBI-298727;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14613483}.
CC       Cytoplasm, cytoskeleton {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P35236-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35236-2; Sequence=VSP_026925;
CC       Name=3;
CC         IsoId=P35236-3; Sequence=VSP_047275;
CC         Note=Ref.4 (BAG54453) sequence is in conflict in position:
CC         37:Q->R. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Expressed exclusively in thymus and spleen.
CC       {ECO:0000269|PubMed:1510684, ECO:0000269|PubMed:1530918}.
CC   -!- PTM: Phosphorylated on serine residues in resting T-cells.
CC       Phosphorylation increases upon exposure to stimuli that increase
CC       intracellular cAMP levels. Phosphorylation leads to dissociation
CC       of bound MAP kinases. {ECO:0000269|PubMed:10206983,
CC       ECO:0000269|PubMed:10559944, ECO:0000269|PubMed:14613483}.
CC   -!- PTM: Oxidized at active site cysteine. Treatment with pervanadate
CC       (vanadate and H(2)O(2)) or with antigen enhanced oxidation of
CC       active site cysteine (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59531.1; Type=Frameshift; Positions=5; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTPN7ID41921ch1q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D11327; BAA01946.1; -; mRNA.
DR   EMBL; M64322; AAA59531.1; ALT_FRAME; mRNA.
DR   EMBL; BT009848; AAP88850.1; -; mRNA.
DR   EMBL; AK127214; BAG54453.1; -; mRNA.
DR   EMBL; AL592300; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001746; AAH01746.2; -; mRNA.
DR   CCDS; CCDS1422.1; -. [P35236-2]
DR   CCDS; CCDS1423.2; -. [P35236-3]
DR   PIR; JH0692; JH0692.
DR   RefSeq; NP_002823.3; NM_002832.3. [P35236-3]
DR   RefSeq; NP_542155.1; NM_080588.2. [P35236-2]
DR   UniGene; Hs.402773; -.
DR   PDB; 1ZC0; X-ray; 1.85 A; A=65-360.
DR   PDB; 2A3K; X-ray; 2.55 A; A=65-358.
DR   PDB; 2GP0; X-ray; 2.05 A; A=65-360.
DR   PDB; 2GPH; X-ray; 1.90 A; B=37-52.
DR   PDB; 2HVL; X-ray; 2.40 A; A=65-360.
DR   PDB; 2QDC; X-ray; 2.00 A; A=65-360.
DR   PDB; 2QDM; X-ray; 2.05 A; A=65-360.
DR   PDB; 2QDP; X-ray; 2.72 A; A=65-360.
DR   PDB; 3D42; X-ray; 2.46 A; A=65-360.
DR   PDB; 3D44; X-ray; 1.90 A; A=65-360.
DR   PDB; 3O4S; X-ray; 1.90 A; A=65-360.
DR   PDB; 3O4T; X-ray; 2.60 A; A=65-360.
DR   PDB; 3O4U; X-ray; 2.25 A; A=65-360.
DR   PDBsum; 1ZC0; -.
DR   PDBsum; 2A3K; -.
DR   PDBsum; 2GP0; -.
DR   PDBsum; 2GPH; -.
DR   PDBsum; 2HVL; -.
DR   PDBsum; 2QDC; -.
DR   PDBsum; 2QDM; -.
DR   PDBsum; 2QDP; -.
DR   PDBsum; 3D42; -.
DR   PDBsum; 3D44; -.
DR   PDBsum; 3O4S; -.
DR   PDBsum; 3O4T; -.
DR   PDBsum; 3O4U; -.
DR   ProteinModelPortal; P35236; -.
DR   SMR; P35236; -.
DR   BioGrid; 111743; 8.
DR   DIP; DIP-29118N; -.
DR   IntAct; P35236; 7.
DR   MINT; MINT-8206881; -.
DR   STRING; 9606.ENSP00000309116; -.
DR   BindingDB; P35236; -.
DR   ChEMBL; CHEMBL2219; -.
DR   DEPOD; P35236; -.
DR   iPTMnet; P35236; -.
DR   PhosphoSitePlus; P35236; -.
DR   DMDM; 20141721; -.
DR   EPD; P35236; -.
DR   MaxQB; P35236; -.
DR   PaxDb; P35236; -.
DR   PeptideAtlas; P35236; -.
DR   PRIDE; P35236; -.
DR   DNASU; 5778; -.
DR   Ensembl; ENST00000309017; ENSP00000309116; ENSG00000143851. [P35236-3]
DR   Ensembl; ENST00000367279; ENSP00000356248; ENSG00000143851. [P35236-2]
DR   Ensembl; ENST00000495688; ENSP00000420506; ENSG00000143851. [P35236-1]
DR   GeneID; 5778; -.
DR   KEGG; hsa:5778; -.
DR   UCSC; uc001gxl.2; human. [P35236-1]
DR   CTD; 5778; -.
DR   DisGeNET; 5778; -.
DR   GeneCards; PTPN7; -.
DR   H-InvDB; HIX0001472; -.
DR   HGNC; HGNC:9659; PTPN7.
DR   HPA; CAB009530; -.
DR   HPA; HPA019118; -.
DR   MIM; 176889; gene.
DR   neXtProt; NX_P35236; -.
DR   OpenTargets; ENSG00000143851; -.
DR   PharmGKB; PA34003; -.
DR   eggNOG; KOG0789; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136384; -.
DR   HOGENOM; HOG000294188; -.
DR   HOVERGEN; HBG001594; -.
DR   InParanoid; P35236; -.
DR   KO; K18019; -.
DR   OrthoDB; EOG091G0HLB; -.
DR   PhylomeDB; P35236; -.
DR   TreeFam; TF331016; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   SABIO-RK; P35236; -.
DR   SIGNOR; P35236; -.
DR   ChiTaRS; PTPN7; human.
DR   EvolutionaryTrace; P35236; -.
DR   GeneWiki; PTPN7; -.
DR   GenomeRNAi; 5778; -.
DR   PRO; PR:P35236; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143851; -.
DR   CleanEx; HS_PTPN7; -.
DR   ExpressionAtlas; P35236; baseline and differential.
DR   Genevisible; P35236; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; TAS:ProtInc.
DR   GO; GO:0006470; P:protein dephosphorylation; TAS:ProtInc.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR008356; Tyr_Pase_KIM-con.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PRINTS; PR01778; KIMPTPASE.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Hydrolase; Oxidation; Phosphoprotein;
KW   Protein phosphatase; Reference proteome.
FT   CHAIN         1    360       Tyrosine-protein phosphatase non-receptor
FT                                type 7.
FT                                /FTId=PRO_0000094761.
FT   DOMAIN       97    350       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION       38     51       Interaction with MAP kinases.
FT   REGION      291    297       Substrate binding.
FT   ACT_SITE    291    291       Phosphocysteine intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160,
FT                                ECO:0000255|PROSITE-ProRule:PRU10044,
FT                                ECO:0000269|PubMed:9624114}.
FT   BINDING     257    257       Substrate.
FT   BINDING     335    335       Substrate.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10559944,
FT                                ECO:0000269|PubMed:14613483}.
FT   MOD_RES      66     66       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10206983}.
FT   MOD_RES      93     93       Phosphoserine.
FT                                {ECO:0000269|PubMed:10206983}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     143    143       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     291    291       Cysteine sulfenic acid (-SOH).
FT                                {ECO:0000250}.
FT   VAR_SEQ       1      1       M -> MGASFWPIRQAREQQRRALSFRQTSWLSEPPLGPAP
FT                                HLSM (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_026925.
FT   VAR_SEQ       1      1       M -> MVGKAWPLTHSQGTGPWAPEGHRREAADPWWQRQQA
FT                                QEGRMQLGCAWVAARRGGGRKLASWSLLSPQRQTDRQTDSW
FT                                QEAAWGPQLLQQTSWLSEPPLGPAPHLSM (in isoform
FT                                3). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047275.
FT   MUTAGEN      44     44       S->A: Prevents dissociation of bound MAP
FT                                kinase and enhances their
FT                                dephosphorylation.
FT                                {ECO:0000269|PubMed:14613483}.
FT   MUTAGEN      44     44       S->D: Reduces binding of MAP kinase.
FT                                {ECO:0000269|PubMed:14613483}.
FT   MUTAGEN      66     66       T->A: Prevents dissociation of bound MAP
FT                                kinase and enhances their
FT                                dephosphorylation; when associated with
FT                                A-93. {ECO:0000269|PubMed:10206983}.
FT   MUTAGEN      93     93       S->A: Prevents dissociation of bound MAP
FT                                kinase and enhances their
FT                                dephosphorylation; when associated with
FT                                A-66. {ECO:0000269|PubMed:10206983}.
FT   MUTAGEN     125    125       Y->A: Strongly reduced catalytic
FT                                activity. {ECO:0000269|PubMed:15466470}.
FT   MUTAGEN     257    257       D->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:15466470}.
FT   MUTAGEN     291    291       C->S: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:9624114}.
FT   MUTAGEN     335    335       Q->A: Reduced catalytic activity.
FT                                {ECO:0000269|PubMed:15466470}.
FT   CONFLICT    235    236       QL -> HV (in Ref. 2; AAA59531).
FT                                {ECO:0000305}.
FT   CONFLICT    337    337       A -> D (in Ref. 1; BAA01946).
FT                                {ECO:0000305}.
FT   HELIX        38     41       {ECO:0000244|PDB:2GPH}.
FT   HELIX        67     77       {ECO:0000244|PDB:1ZC0}.
FT   STRAND       81     83       {ECO:0000244|PDB:3D44}.
FT   HELIX        84     89       {ECO:0000244|PDB:1ZC0}.
FT   HELIX        94    103       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       111    113       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       119    122       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       132    134       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      135    137       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      149    155       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       158    160       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      164    169       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       173    175       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       176    185       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      190    194       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      199    201       {ECO:0000244|PDB:3O4S}.
FT   STRAND      210    215       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      218    227       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      229    240       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      243    252       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       264    275       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      281    283       {ECO:0000244|PDB:3D44}.
FT   STRAND      287    295       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       296    314       {ECO:0000244|PDB:1ZC0}.
FT   STRAND      315    317       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       319    329       {ECO:0000244|PDB:1ZC0}.
FT   HELIX       337    353       {ECO:0000244|PDB:1ZC0}.
SQ   SEQUENCE   360 AA;  40529 MW;  388A154CC55AC0EE CRC64;
     MVQAHGGRSR AQPLTLSLGA AMTQPPPEKT PAKKHVRLQE RRGSNVALML DVRSLGAVEP
     ICSVNTPREV TLHFLRTAGH PLTRWALQRQ PPSPKQLEEE FLKIPSNFVS PEDLDIPGHA
     SKDRYKTILP NPQSRVCLGR AQSQEDGDYI NANYIRGYDG KEKVYIATQG PMPNTVSDFW
     EMVWQEEVSL IVMLTQLREG KEKCVHYWPT EEETYGPFQI RIQDMKECPE YTVRQLTIQY
     QEERRSVKHI LFSAWPDHQT PESAGPLLRL VAEVEESPET AAHPGPIVVH CSAGIGRTGC
     FIATRIGCQQ LKARGEVDIL GIVCQLRLDR GGMIQTAEQY QFLHHTLALY AGQLPEEPSP
//
